Align Technology
ALGN
$181.26
+1.57%
Align Technology is the leading manufacturer of clear aligners, primarily known for its Invisalign brand, and also produces iTero intraoral scanners for digital dentistry. The company dominates the clear aligner market with over 90% share and has treated over 14 million patients since launch, positioning it as a near-monopoly in a growing orthodontic segment. The current investor narrative centers on a potential turnaround driven by activist investor Elliott Management's reported large stake, which has sparked hopes for operational improvements and value creation. Additionally, the stock is attracting attention due to its discounted valuation relative to history and the potential for growth acceleration as Invisalign adoption expands among both dentists and consumers.…
ALGN
Align Technology
$181.26
Related headlines
Investment Opinion: Should I buy ALGN Today?
Rating: Buy. The thesis is that Align Technology is a high-quality business with a dominant market position, trading at a deeply discounted forward P/E of 14.51x, with a catalyst from activist investor Elliott Management to unlock value. The consensus analyst rating is bullish, with recent upgrades from Barclays and HSBC, and the average EPS estimate of $15.77 implies significant upside.
Supporting Evidence: The forward P/E of 14.51x is below the sector average of 18x and Align's historical average of ~40x. Revenue is expected to grow 16.7% to $4.89 billion next fiscal year, driven by Invisalign volume growth and scanner adoption. The company generates strong free cash flow ($593.2 million TTM) with a 5.2% yield, and its net margin of 10.2% is healthy. The implied upside to the average analyst target (not explicitly given but based on EPS estimates) suggests a target price around $226 (15.77 * 14.35x forward P/E), representing 26% upside from $179.45.
Risks & Conditions: The biggest risks are failure to achieve the expected earnings recovery and continued revenue deceleration. This Buy rating would be downgraded to Hold if revenue growth falls below 10% in the next two quarters or if gross margins drop below 60%. It would be upgraded to Strong Buy if Elliott announces a specific value creation plan or if the company reports a quarter with revenue growth above 15%. Overall, Align appears undervalued relative to its forward earnings potential and historical multiples, but investors must monitor execution closely.
Sign up to view all
ALGN 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The primary drivers are the deeply discounted forward valuation and the activist catalyst, which together create a favorable risk/reward. However, confidence is tempered by the uncertainty around the earnings recovery and the stock's high beta. The key factor to watch is revenue growth: if it accelerates above 10%, the bull case becomes more likely; if it decelerates below 5%, the bear case materializes. The stance would be upgraded to high confidence if Elliott announces a concrete plan or if Q3 2026 revenue growth exceeds 15%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $235.64 and implied upside of +30.0% versus the current price.
Average Target
$235.64
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$145 - $236
Analyst target range
Based on the limited analyst data available (5 analysts), the consensus recommendation leans bullish, with recent upgrades from Barclays (to Overweight) and HSBC (to Buy). The average estimated EPS for the next fiscal year is $15.77, with a range of $15.57 to $15.98, implying strong earnings growth from the trailing EPS of $1.89 (Q4 2025 annualized). The average revenue estimate is $4.89 billion, suggesting 16.7% growth from the trailing twelve-month revenue of $4.19 billion. The implied upside to the average target cannot be calculated directly due to missing price targets, but the EPS estimates imply a forward P/E of 11.4x at the current price, which is very attractive. The high EPS estimate of $15.98 suggests that some analysts see significant margin expansion or revenue acceleration, while the low estimate of $15.57 indicates a more conservative outlook. The wide range in EPS estimates (2.6% spread) reflects moderate uncertainty. The recent activist involvement and analyst upgrades suggest growing optimism, but the limited coverage (5 analysts) means the stock may be underfollowed, leading to potential inefficiencies. Investors should monitor for additional analyst initiations or target revisions as catalysts emerge.
Bulls vs Bears: ALGN Investment Factors
Align Technology presents a compelling risk/reward opportunity driven by activist involvement, a deeply discounted forward valuation, and a dominant market position. The bull case rests on the potential for Elliott Management to catalyze operational improvements and earnings growth, with forward P/E of 14.51x offering a significant margin of safety. However, the bear case highlights slowing revenue growth, a trailing P/E premium to peers, and the uncertainty around the steep earnings recovery implied by analyst estimates. The single most important tension is whether the company can deliver the expected earnings rebound—if it does, the stock could re-rate substantially higher; if it fails, the current valuation could prove to be a value trap. Overall, the evidence slightly favors the bull case given the activist catalyst and attractive forward multiples, but execution risk remains high.
Bullish
- Activist Catalyst from Elliott Management: Elliott Management's reported large stake in Align Technology provides a powerful catalyst for operational improvements and value creation. Activist involvement often leads to cost cuts, strategic refocusing, or a sale, which could unlock significant shareholder value given the stock's depressed valuation.
- Compelling Forward Valuation: The forward P/E of 14.51x is well below the sector average of 18x and Align's historical average of ~40x. This implies the market is pricing in a significant earnings recovery, with analysts estimating EPS of $15.77 for the next fiscal year, representing a 735% increase from trailing EPS of $1.89.
- Dominant Market Position with High Margins: Align controls over 90% of the clear aligner market with its Invisalign brand, and its gross margin of 68.3% and operating margin of 15.3% demonstrate strong pricing power and operational efficiency. The company's near-monopoly in a growing market provides a durable competitive advantage.
- Strong Balance Sheet and Cash Flow: With a debt-to-equity ratio of just 0.028 and trailing free cash flow of $593.2 million, Align has a fortress balance sheet. The free cash flow yield of approximately 5.2% is attractive for a growth company, providing financial flexibility for buybacks, investments, or M&A.
Bearish
- Revenue Growth Deceleration: Revenue growth has slowed significantly, with Q4 2025 revenue up only 5.26% YoY and Q1 2025 revenue actually declining 1.8% YoY. This deceleration raises concerns about market saturation and increased competition from companies like SmileDirectClub and Dentsply Sirona.
- Trailing P/E Premium to Peers: The trailing P/E of 27.59x is 25% above the Medical Devices sector average of 22x. This premium may be unjustified given the slowing growth, and if earnings fail to recover as expected, the stock could de-rate further, compressing the multiple.
- High Beta and Macro Sensitivity: With a beta of 1.669, Align is significantly more volatile than the market. In a rising interest rate environment or economic downturn, the stock could underperform. The 1-year price change of -12.24% versus the S&P 500's +20.63% highlights this vulnerability.
- Uncertainty Around Earnings Recovery: The massive gap between trailing EPS of $1.89 and forward EPS estimates of $15.77 implies an extraordinary earnings recovery that may be overly optimistic. If the recovery disappoints, the stock could face significant downside as the forward P/E adjusts upward.
ALGN Technical Analysis
Align Technology's stock is in a recovery phase after a prolonged downtrend, with the 1-year price change of -12.24% reflecting significant underperformance versus the S&P 500's +20.63% gain. The current price of $179.45 sits at 60.5% of its 52-week range ($122.00 low to $208.31 high), indicating it has rebounded from the lows but remains well below the highs. This positioning suggests the stock is in a rebuilding phase, with potential for further upside if momentum continues, but still carries the weight of past losses. Short-term momentum is positive, with the 1-month price change of +5.25% and 3-month change of +3.64%, both outpacing the S&P 500's 1-month return of 4.07% but lagging its 3-month return of 11.11%. The 1-month relative strength of 1.18 indicates outperformance versus the market, but the 3-month relative strength of -7.47 shows that the longer-term trend remains bearish relative to the broad market. This divergence suggests the stock may be in the early stages of a trend reversal, but confirmation requires sustained buying. The 52-week high of $208.31 acts as key resistance, while the 52-week low of $122.00 provides support. A breakout above $208.31 would signal a potential trend reversal and target higher levels, while a breakdown below $122.00 would indicate further downside. The stock's beta of 1.669 implies it is 66.9% more volatile than the market, meaning it amplifies market moves—a factor that increases risk but also offers greater upside potential in a bullish scenario. The short ratio of 4.46 days suggests elevated short interest, which could fuel a short squeeze if positive catalysts emerge.
Beta
1.67
1.67x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$122-$208
Price range past year
Annual Return
-6.0%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | +1.7% | +0.0% |
| 3m | -2.0% | +7.6% |
| 6m | +5.7% | +9.1% |
| 1y | -6.0% | +21.3% |
| ytd | +16.2% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Align Technology's revenue trajectory shows moderate growth, with Q4 2025 revenue of $1.0476 billion, up 5.26% year-over-year from $995.2 million in Q4 2024. However, the multi-quarter trend reveals deceleration: Q2 2025 revenue was $1.0124 billion (up 1.5% YoY from $1.0285 billion in Q2 2024), and Q1 2025 revenue was $979.3 million (down 1.8% YoY from $997.4 million in Q1 2024). The Clear Aligner segment generated $794.3 million in Q4 2025, while Scanners and Services contributed $200.9 million, indicating the core aligner business drives 79% of revenue. The growth deceleration raises questions about market saturation and competition, but the recent activist involvement may spur initiatives to reignite growth. Profitability remains solid, with Q4 2025 net income of $135.8 million and a net margin of 12.96%, up from 10.43% in Q4 2024. Gross margin was 65.69% in Q4 2025, slightly down from 70.03% in Q4 2024, but still healthy. Operating margin improved to 15.23% from 14.48% a year ago, indicating better cost control. The company is consistently profitable, with trailing twelve-month free cash flow of $593.2 million, providing ample liquidity. The balance sheet is strong, with a debt-to-equity ratio of just 0.028, virtually no debt, and a current ratio of 1.36. Return on equity (ROE) stands at 10.13%, while return on assets (ROA) is 7.23%, reflecting efficient capital use. Free cash flow yield (FCF/price) is approximately 5.2%, which is attractive for a growth company. The company generates sufficient cash to fund operations and growth without relying on external financing.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+5.3%
YoY Comparison
Gross Margin
65.7%
Latest Quarter
Free Cash Flow
$593223000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 27.59x, while the forward P/E is 14.51x, implying the market expects significant earnings growth. The large gap between trailing and forward P/E suggests that analysts anticipate a sharp earnings recovery, likely driven by cost initiatives and volume growth. Compared to the industry (Medical Devices), Align's trailing P/E of 27.59x is above the sector average of roughly 22x, representing a 25% premium. However, the forward P/E of 14.51x is below the sector average of 18x, indicating that the market is pricing in above-average earnings growth. The premium on trailing earnings may reflect the company's dominant market position and high margins, but the discount on forward earnings suggests skepticism about near-term growth. Historically, Align's trailing P/E has ranged from 20x to over 70x in the past five years. The current 27.59x is near the lower end of that range, suggesting the stock is relatively cheap by its own historical standards. The P/E was as high as 73x in early 2023 and as low as 20x in late 2025, so the current level is below the historical average of around 40x. This low multiple could indicate a value opportunity if the company can return to growth, or it could reflect structural challenges that justify a lower valuation.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Align's primary financial risk is the reliance on a steep earnings recovery to justify its forward valuation. Trailing EPS of $1.89 implies a P/E of 27.59x, but forward EPS estimates of $15.77 require a 735% increase. If revenue growth continues to decelerate (Q1 2025 revenue declined 1.8% YoY) or margins compress (gross margin fell from 70.0% in Q4 2024 to 65.7% in Q4 2025), the earnings recovery may fall short, leading to multiple expansion and stock price decline. The company's debt-free balance sheet and strong free cash flow ($593.2 million TTM) mitigate liquidity risk, but the high operating leverage means that any revenue shortfall directly impacts profitability.
Market & Competitive Risks: Align's near-monopoly in clear aligners faces growing competition from Dentsply Sirona (SureSmile), 3M (Clarity Aligners), and direct-to-consumer players. The stock's beta of 1.669 indicates high sensitivity to market movements, and its 1-year relative strength of -32.87% versus the S&P 500 shows it has been a significant underperformer. Valuation compression risk is elevated: the trailing P/E of 27.59x is above the sector average of 22x, and if growth disappoints, the multiple could contract to 20x or lower. The recent activist news (Elliott stake) could lead to positive changes but also introduces uncertainty around potential restructuring or sale processes.
Worst-Case Scenario: If the earnings recovery fails to materialize due to sustained revenue deceleration and margin pressure, the stock could fall to its 52-week low of $122.00, representing a 32% decline from the current price of $179.45. This scenario would likely involve multiple quarters of missed estimates, analyst downgrades, and loss of investor confidence. The historical max drawdown of -39.73% suggests that in a severe downturn, the stock could fall to around $108, a 40% loss. Investors should be prepared for significant volatility given the high beta and short interest.
FAQ
The key risks are: (1) Earnings recovery failure: The forward EPS estimate of $15.77 requires a 735% increase from trailing EPS of $1.89; any shortfall could lead to multiple expansion and stock price decline. (2) Revenue deceleration: Q1 2025 revenue declined 1.8% YoY, and if this trend continues, the bull case collapses. (3) Competitive pressure: Despite a 90% market share, competitors like Dentsply Sirona and direct-to-consumer brands could erode Align's dominance. (4) Macro sensitivity: With a beta of 1.669, the stock is highly correlated to market moves, and a downturn could amplify losses. The most severe risk is a sustained growth slowdown that prevents the earnings recovery, potentially driving the stock to its 52-week low of $122, a 32% downside.
The 12-month forecast is based on three scenarios. The base case (45% probability) sees the stock trading between $180 and $210, driven by moderate revenue growth of 10-12% and stable margins. The bull case (30% probability) targets $210-$240, catalyzed by activist-driven improvements and strong earnings. The bear case (25% probability) sees the stock falling to $122-$160 if the earnings recovery fails. The most likely scenario is the base case, assuming the company executes a gradual turnaround. The average analyst EPS estimate of $15.77 implies a forward P/E of 11.4x at the current price, suggesting significant upside if achieved. Investors should monitor quarterly results for confirmation of the recovery trajectory.
Align Technology appears undervalued on a forward basis but overvalued on a trailing basis relative to peers. The forward P/E of 14.51x is below the Medical Devices sector average of 18x and Align's historical average of ~40x, suggesting the market is pricing in a significant earnings recovery. However, the trailing P/E of 27.59x is 25% above the sector average of 22x, indicating that the stock is expensive based on past earnings. The large gap between trailing and forward P/E implies that analysts expect a sharp earnings rebound, with EPS growing from $1.89 to $15.77. If this recovery materializes, the stock is undervalued; if not, it could be a value trap. The PEG ratio of 51.77x is extremely high, reflecting the low current earnings base.
Align Technology presents a compelling risk/reward for investors willing to tolerate high volatility. The stock trades at a forward P/E of 14.51x, well below the sector average of 18x and its historical average of ~40x, implying significant upside if earnings recover as expected. The activist involvement from Elliott Management adds a catalyst for value creation. However, the trailing P/E of 27.59x is above peers, and the earnings recovery is uncertain. For long-term investors with a 12-18 month horizon, ALGN is a good buy given the discounted valuation and activist catalyst, but it is not suitable for risk-averse investors or those with a short-term focus due to its high beta (1.669) and short interest (4.46 days).
Align Technology is best suited for a medium-term investment horizon of 12-18 months, given the activist catalyst and expected earnings recovery. The stock's high beta (1.669) and short ratio (4.46 days) make it volatile for short-term trading, but the discounted forward valuation provides a margin of safety for longer-term holders. The company does not pay a dividend, so income investors should look elsewhere. For long-term investors (3+ years), the dominant market position and high margins offer compounding potential, but the current uncertainty around growth makes it a higher-risk hold. A minimum holding period of 12 months is recommended to allow the activist catalyst and earnings recovery to play out.